The U.S. Food and Drug Administration (FDA) has ushered in a new era in cancer treatment with the approval of Tecelra (afamitresgene autoleucel), an innovative therapy aimed at combating synovial sarcoma. This rare and aggressive form of cancer predominantly impacts young adults and has
The recent collaboration between biotech creation engines Two River and Third Rock Ventures has led to the formation of TRC 2004, which has licensed a bispecific T-cell engager (BiTE) from Genor Biopharma. TRC 2004 has acquired the ex-China rights to the CD20/CD3-targeting BiTE, known as GB261,
The biotech industry has seen a flurry of activity, with companies undertaking significant workforce restructuring, achieving crucial FDA approvals, and navigating the complex landscape of clinical trials. These developments reflect both the challenges and advancements within the sector, offering a
Jim Wilson, a seminal figure in the field of gene therapy, is departing the University of Pennsylvania (UPenn) after an illustrious career spanning decades. His decision to step down marks a significant juncture for both the institution and the broader gene therapy landscape. Over the years, Wilson
The field of autoimmune disease treatment is witnessing groundbreaking innovations, with Cartesian Therapeutics making headlines for its latest Phase 2 clinical trial results of Descartes-08. This experimental cell therapy aims to bring hope to patients suffering from myasthenia gravis, a rare and
Artiva Biotherapeutics has made headlines with its successful initial public offering (IPO), raising an impressive $167 million. This significant milestone not only highlights Artiva's strategic pivot toward autoimmune disease treatments using donor-derived cell therapies but also marks a broader
